| Name | Title | Contact Details |
|---|
Rooted in Relationships, Backed by Results. Our Mission is to revolutionize the perception and impact of employee well-being by creating and proving the correlation of employee well-being with bottom line revenue. To help medium and large-sized organizations by deploying and managing tailored programs that are customized for every client and personalized for each participant. To deliver total Return on Well-being for every client, including individual health improvement, heightened employee engagement, increased productivity, cultural improvement, lower healthcare costs, and higher profitability. Our Vision is to revolutionize the way corporate America values employee well-being by correlating improved employee health and employee engagement with decreased human resources costs and improved financial performance. Our Purpose is to impact our clients’ success and the quality of life of each individual we touch. Through Guaranteed Support; Guaranteed Enjoyment; Guaranteed Improvement you’ll see how we can impact your Return on Well-being (ROW) and improve the health and well-being of your workforce. Connect with us to start the change!
Robin Medical is a Pikesville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Grifols is a global healthcare company whose mission is to improve the health and well being of people around the world. We accomplish this mission by producing life-saving protein therapies for patients and by providing hospitals, pharmacies and healthcare professionals with the tools they need to deliver expert medical care. We have three primary divisions Bioscience, Diagnostic and Hospital – which develop, produce and market our innovative products and services to medical professionals in more than 90 countries around the world.
Central Massachusetts Independent Physician Association is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.